|
Characteristic
|
N (%)
|
|---|
|
Age
|
|
< 75 years
|
319 (82.0)
|
|
≥ 75 years
|
70 (18.0)
|
|
Median (range) age, years 65 (34–85)
|
|
Gender
|
|
Male
|
291 (74.8)
|
|
Female
|
98 (25.2)
|
|
ECOG performance status
|
|
0
|
176 (47.1)
|
|
1
|
174 (46.5)
|
|
2
|
24 (6.4)
|
|
NA
|
15
|
|
IMDC prognostic group
|
|
Favourable
|
62 (20.2)
|
|
Intermediate
|
212 (69.1)
|
|
Poor
|
33 (10.7)
|
|
NA
|
82
|
|
Nephrectomy
|
|
Yes
|
369 (94.9)
|
|
No
|
20 (5.1)
|
|
Histology
|
|
Clear-cell
|
356 (91.5)
|
|
Non-clear-cell
|
26 (6.7)
|
|
Undifferentiated/Unknown
|
7 (1.8)
|
|
Metastasis site
|
|
Lung
|
286 (73.5)
|
|
Lymph node
|
238 (69.2)
|
|
Bone
|
193 (49.6)
|
|
Liver
|
128 (32.9)
|
|
Brain
|
32 (8.2)
|
|
Number of prior systemic therapies
|
|
1
|
80 (20.7)
|
|
2
|
137 (35.4)
|
|
≥ 3
|
170 (43.9)
|
|
First-line therapy
|
|
Sunitinib
|
261 (67.4)
|
|
Pazopanib
|
80 (20.7)
|
|
Other
|
46 (11.9)
|
|
Prior everolimus
|
|
Yes
|
163 (42.1)
|
|
No
|
224 (57.9)
|
- Abbreviations: N number, NA not assessed, ECOG Eastern Cooperative Oncology Group, IMDC International Metastatic Renal Cell Carcinoma Database Consortium
